Novartis announced today that the U.S. Food and Drug Administration accepted the company’s supplemental New Drug Application and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy for the first-line treatment of severe aplastic anemia.
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade® (eltrombopag), […]
